Insider Trading Alert - GM, LOGM And ANAC Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, May 1, 2015, 63 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $200.00 to $4,632,380.28.

Highlighted Stocks Traded by Insiders:

General Motors (GM) - FREE Research Report

Russo Patricia F, who is Director at General Motors, bought 1,500 shares at $35.59 on May 1, 2015. Following this transaction, the Director owned 2,300 shares meaning that the stake was boosted by 187.5% with the 1,500-share transaction.

Gooden Linda R, who is Director at General Motors, bought 1,000 shares at $35.37 on May 1, 2015. Following this transaction, the Director owned 1,000 shares meaning that the stake was boosted by 100% with the 1,000-share transaction.

The shares most recently traded at $35.58, up $0.21, or 0.59% since the insider transaction. Historical insider transactions for General Motors go as follows:

  • 4-Week # shares sold: 73.4 million
  • 12-Week # shares sold: 73.4 million
  • 24-Week # shares sold: 73.4 million

The average volume for General Motors has been 16.3 million shares per day over the past 30 days. General Motors has a market cap of $56.3 billion and is part of the consumer goods sector and automotive industry. Shares are up 1.46% year-to-date as of the close of trading on Friday.

General Motors Company designs, builds, and sells cars, crossovers, trucks, and automobile parts worldwide. It operates through GM North America, GM Europe, GM International Operations, GM South America, and GM Financial segments. The stock currently has a dividend yield of 4.11%. The company has a P/E ratio of 16.3. Currently, there are 8 analysts who rate General Motors a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GM - FREE

TheStreet Quant Ratings rates General Motors as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, impressive record of earnings per share growth, notable return on equity and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full General Motors Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

LogMeIn (LOGM) - FREE Research Report

Ford W. Sean, who is SVP & Chief Marketing Officer at LogMeIn, sold 3,937 shares at $64.64 on May 1, 2015. Following this transaction, the SVP & Chief Marketing Officer owned 0 shares meaning that the stake was reduced by 100% with the 3,937-share transaction.

Herdiech Edward K., who is Chief Financial Officer at LogMeIn, sold 2,704 shares at $64.33 on May 1, 2015. Following this transaction, the Chief Financial Officer owned 1,506 shares meaning that the stake was reduced by 64.23% with the 2,704-share transaction.

The shares most recently traded at $64.55, up $0.22, or 0.35% since the insider transaction. Historical insider transactions for LogMeIn go as follows:

  • 4-Week # shares sold: 2,500
  • 12-Week # shares sold: 2,500
  • 24-Week # shares sold: 2,500

The average volume for LogMeIn has been 281,000 shares per day over the past 30 days. LogMeIn has a market cap of $1.6 billion and is part of the technology sector and computer software & services industry. Shares are up 29.51% year-to-date as of the close of trading on Friday.

LogMeIn, Inc. provides cloud-based services for individuals and businesses to securely connect to their workplace, colleagues, and customers. The company has a P/E ratio of 188.8. Currently, there are 6 analysts who rate LogMeIn a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LOGM - FREE

TheStreet Quant Ratings rates LogMeIn as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full LogMeIn Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Anacor Pharmaceuticals (ANAC) - FREE Research Report

Maples Kirk R, who is SVP, Program Management at Anacor Pharmaceuticals, sold 600 shares at $53.95 on May 1, 2015. Following this transaction, the SVP, Program Management owned 7,820 shares meaning that the stake was reduced by 7.13% with the 600-share transaction.

Sullivan Ryan T, who is Sr. VP and General Counsel at Anacor Pharmaceuticals, sold 3,125 shares at $53.61 on May 1, 2015. Following this transaction, the Sr. VP and General Counsel owned 27,740 shares meaning that the stake was reduced by 10.12% with the 3,125-share transaction.

The shares most recently traded at $56.66, up $3.05, or 5.38% since the insider transaction. Historical insider transactions for Anacor Pharmaceuticals go as follows:

  • 4-Week # shares sold: 50,000
  • 12-Week # shares sold: 97,700
  • 24-Week # shares sold: 160,748

The average volume for Anacor Pharmaceuticals has been 651,600 shares per day over the past 30 days. Anacor Pharmaceuticals has a market cap of $2.3 billion and is part of the health care sector and drugs industry. Shares are up 68.68% year-to-date as of the close of trading on Friday.

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It markets KERYDIN (tavaborole) topical solution for the treatment of onychomycosis of the toenails. Currently, there are 4 analysts who rate Anacor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANAC - FREE

TheStreet Quant Ratings rates Anacor Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Anacor Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Data for this article provided by Zacks Investment Research

More from Markets

Asian Markets Decline in Morning Trading

Asian Markets Decline in Morning Trading

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call